Content
Frontiers of Medicine >> 2021, Volume 15, Issue 5 doi: 10.1007/s11684-021-0853-6
Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial
. Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.. The First Affiliated Hospital of University of Science and Technology of China, Hefei 230026, China.. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.. Harbin Pharmaceutical Group Co., Ltd., Harbin 150070, China.. The Sixth Hospital of Harbin, Harbin 150036, China.. The Second Hospital of Nanjing and the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210003, China.. Department of Cardiology, Chinese People’s Liberation Army Central War Command General Hospital, Wuhan 430010, China.. Department of Information Management, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.. Division of Respiratory, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.. Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
Abstract
Keywords
COVID-19 ; SARS-CoV-2 ; Shuanghuanglian oral liquid ; clinical trial
Content